Evaluation of AMG 420, an anti-BCMA bispecific T-cell engager (BiTE) immunotherapy in patients with R R multiple myeloma from 420 bi i Watch Video
Preview(s):
Gallery
Play Video: (Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
Description: Prof Max Topp talks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about the results from a first in-human phase I dose escalation study using the bispecific antibody construct, AMG 420 in patients with relapsed/refractory multiple myeloma. nnHe explains the use of AMG 420, along with the primary objectives, safety and tolerability of the drug. Secondary endpoints included anti-tumour probabilities of this therapy.nnProf Topp reports that the maximum tolerated
Play Video: (Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)